Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination.

Sudarshini RamanathanShekeeb MohammadEsther TantsisTina Kim NguyenVera MerhebVictor S C FungOwen Bruce WhiteSimon BroadleyJeannette Lechner-ScottSteve VucicAndrew P D HendersonMichael Harry BarnettStephen W ReddelFabienne BrilotRussell C Dalenull null

Published in: Journal of neurology, neurosurgery, and psychiatry (2017)

Relapsing MOG antibody-associated demyelination is strongly associated with ON across all age groups and ADEM in children. Patients are highly responsive to steroids, but vulnerable to relapse on steroid reduction and cessation.

Keyphrases

multiple sclerosis
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
young adults
prognostic factors
peritoneal dialysis
cancer therapy
patient reported